Browsing by Subject "Clinical Trials as Topic"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
Item COVID-19 clinical trial participation and awareness in Texas(Informa UK Limited, trading as Taylor & Francis Group, 2024-04-25) Luningham, Justin M.; Akpan, Idara N.; Alkhatib, Sarah; Taskin, Tanjila; Desai, Palak; Vishwanatha, Jamboor K.; Thompson, Erika L.The COVID-19 pandemic required the rapid development of COVID-19 vaccines and treatments, necessitating quick yet representative clinical trial enrollment to evaluate these preventive measures. However, misinformation around the COVID-19 pandemic and general concerns about clinical trial participation in the U.S. hindered clinical trial enrollment. This study assessed awareness of, willingness to participate in, and enrollment in COVID-19 vaccine and treatment clinical trials in Texas. A quota sample of 1,089 Texas residents was collected online from June - July 2022. Respondents were asked if they were aware of, willing to participate in, and had enrolled in clinical trials for COVID-19 vaccines or treatments. Overall, 45.8% of respondents reported being aware of clinical trials for COVID-19 treatments or vaccines, but only 21.7% knew how to enroll and only 13.2% had enrolled in a COVID-19 clinical trial. Respondents with bachelor's or graduate degrees were more likely to be aware of clinical trials, more likely to have enrolled in trials, and more willing to participate in treatment trials. Women were less willing to participate and less likely to have enrolled in COVID-19 clinical trials than men. Respondents aged 55 years and older were more willing to participate, but less likely to have enrolled in COVID-19 clinical trials than 18-to-24-year-olds. Common reasons given for not participating in clinical trials included concerns that COVID-19 treatments may not be safe, government distrust, and uncertainty about what clinical trial participation would entail. Substantial progress is needed to build community awareness and increase enrollment in clinical trials.Item Qualitative Analysis on HIV/AIDS Clinical Trial Recruitment Marketing Practices(2022-05) Dapoz, Anthony M., Jr.; Simecka, Jerry W.Recruitment continues to be one of the largest barriers to clinical trial success. Based on review of clinical trial marketing literature, there are no marketing industry standards established for recruitment of HIV/AIDS clinical trials. The purpose of this study was to begin finding optimal marketing recruitment strategies in HIV/AIDS clinical trials research. A literature review yielded 20 articles detailing recruitment marketing practices. A ClinicalTrials.gov search found 57 trials meeting inclusion criteria. Data extracted included recruitment strategies, original enrollment goals, estimated enrollment goals and actual enrollment goals. Regression analysis found no significant relationship between marketing strategies and recruitment rate. Added financial and managerial considerations should be incorporated with a robust site level marketing campaign to optimize recruitment potential.Recruitment continues to be one of the largest barriers to clinical trial success. Based on review of clinical trial marketing literature, there are no marketing industry standards established for recruitment of HIV/AIDS clinical trials. The purpose of this study was to begin finding optimal marketing recruitment strategies in HIV/AIDS clinical trials research. A literature review yielded 20 articles detailing recruitment marketing practices. A ClinicalTrials.gov search found 57 trials meeting inclusion criteria. Data extracted included recruitment strategies, original enrollment goals, estimated enrollment goals and actual enrollment goals. Regression analysis found no significant relationship between marketing strategies and recruitment rate. Added financial and managerial considerations should be incorporated with a robust site level marketing campaign to optimize recruitment potential.Item The Future of Medicine: Expoloring the Acceleration of Drug Development with Decentralized Clinical Trials(2023-12) Ajape, Opemipo; Zascavage, Roxanne R.The present study explores the transformative potential of Decentralized Clinical Trials (DCT) within the field of medical research. The primary objective is to investigate how the adoption of DCT influences efficiency, patient engagement, and data quality in medical research. DCT offers the potential to streamline data collection, reduce administrative complexities, and overcome geographical constraints. This is achieved through real-time monitoring, electronic data capture, and remote data gathering techniques, making it particularly advantageous in complex scenarios like rare disease research. These efficiencies can expedite drug development, ensuring timely access to novel treatments; however, concerns about data security and privacy must be addressed to sustain these benefits. Patient engagement is a significant advantage of DCT. It allows patients to participate in research remotely, removing geographical barriers and promoting inclusion. The patient-centric approach in DCT design enhances diversity, recruitment, and retention rates. Nonetheless, maintaining patient engagement may be challenging due to limited face-to-face interactions with healthcare professionals. Data quality in DCT depends on methodologies that generate substantial data, but this complexity requires advanced analytics. DCT emphasizes a practical approach to clinical research, prioritizing patient care and valuable data collection. Ensuring the exclusion of ineligible or fraudulent participants, especially in cases involving financial incentives, is crucial. The implementation of Decentralized Clinical Trials holds the promise of fundamentally transforming medical research by enhancing efficiency, inclusivity, and data-centricity in trials. While challenges exist, current research suggests that the advantages of DCT outweigh the obstacles, paving the way for advancements in medical practices.